Additionally, Hiroto Takeya et al. revealed a positive association between higher CD169 expression and density of tumor-infiltrating lymphocytes in esophageal cancer who underwent neoadjuvant chemotherapy, indicating that high CD169 expression plays a crucial role in inducing anti-cancer immune responses [19]. This evidence concerns the gene SIGLEC1 and esophageal cancer.